Sequencing:Article Title: Interventions for renal vasculitis in adults
Article Snippet: BVAS reduction of 50% between entry and 3 months Secondary outcomes • Fall in BVAS, CRP and ANCA• Relapse at 3 months• Reduction in immunosuppressive drug doses• Adverse effects Notes • Funding source: "This trial was supported by a grant and provision of trial medication from Novartis Pharmaceuticals UK." .. Bias Authors' judgement Support for judgement Random sequence generation (selection bias) Low risk "Randomisation and distribution of trial medication was centrally controlled by Novartis UK" Allocation concealment (selection bias) Low risk Medication distributed by Novartis UK Blinding of participants and personnel (performance bias) All outcomes Low risk "patients and physicians were blinded to the treatment limb" Blinding of outcome assessment (detection bias) All outcomes Unclear risk Insufficient information to permit judgement Incomplete outcome data (attrition bias) All outcomes Low risk All patients accounted for Selective reporting (reporting bias) Low risk Study and review outcomes reported Other bias High risk Funding source: Novartis Jayne 2000 (Continued) Methods • Study design: parallel, open-label, pragmatic, multicentre, RCT• Duration of study: enrolment November 2012 to November 2013 MAINRITSAN 2 2018 Interventions for renal vasculitis in adults (Review) Copyright © 2020 The Cochrane Collaboration. ..
Article Title: Interventions for renal vasculitis in adults
Article Snippet: BVAS reduction of 50% between entry and 3 months Secondary outcomes Fall in BVAS, CRP and ANCA Relapse at 3 months Reduction in immunosuppressive drug doses Adverse effects Notes Funding source: "This trial was supported by a grant and provision of trial medication from Novartis Pharmaceuticals UK." .. Risk of bias Bias Authors' judgement Support for judgement Random sequence generation (selection bias) Low risk "Randomisation and distribution of trial medication was centrally controlled by Novartis UK" Allocation concealment (selection bias) Low risk Medication distributed by Novartis UK Blinding of participants and personnel (performance bias) All outcomes Low risk "patients and physicians were blinded to the treatment limb" Blinding of outcome assessment (detection bias) All outcomes Unclear risk Insufficient information to permit judgement Incomplete outcome data (attrition bias) All outcomes Low risk All patients accounted for Selective reporting (reporting bias) Low risk Study and review outcomes reported Other bias High risk Funding source: Novartis Jayne 2000 Methods Study design: parallel, open‐label, pragmatic, multicentre, RCT Duration of study: enrolment November 2012 to November 2013 Duration of follow‐up: 28 months Participants Country: France Setting: multicentre (59 sites) Inclusion criteria: > 18 years; had newly diagnosed or relapsing GPA or MPA (defined by the Chapel Hill Consensus nomenclature); in complete remission after induction therapy, combining glucocorticoids and cyclophosphamide, RTX or methotrexate (as decided by each investigator), in accordance with French and international recommendations; BVAS of 0 (score range: 0–63, with higher scores indicating more active disease) defined complete remission. ..
Selection:Article Title: Interventions for renal vasculitis in adults
Article Snippet: BVAS reduction of 50% between entry and 3 months Secondary outcomes • Fall in BVAS, CRP and ANCA• Relapse at 3 months• Reduction in immunosuppressive drug doses• Adverse effects Notes • Funding source: "This trial was supported by a grant and provision of trial medication from Novartis Pharmaceuticals UK." .. Bias Authors' judgement Support for judgement Random sequence generation (selection bias) Low risk "Randomisation and distribution of trial medication was centrally controlled by Novartis UK" Allocation concealment (selection bias) Low risk Medication distributed by Novartis UK Blinding of participants and personnel (performance bias) All outcomes Low risk "patients and physicians were blinded to the treatment limb" Blinding of outcome assessment (detection bias) All outcomes Unclear risk Insufficient information to permit judgement Incomplete outcome data (attrition bias) All outcomes Low risk All patients accounted for Selective reporting (reporting bias) Low risk Study and review outcomes reported Other bias High risk Funding source: Novartis Jayne 2000 (Continued) Methods • Study design: parallel, open-label, pragmatic, multicentre, RCT• Duration of study: enrolment November 2012 to November 2013 MAINRITSAN 2 2018 Interventions for renal vasculitis in adults (Review) Copyright © 2020 The Cochrane Collaboration. ..
Article Title: Interventions for renal vasculitis in adults
Article Snippet: BVAS reduction of 50% between entry and 3 months Secondary outcomes Fall in BVAS, CRP and ANCA Relapse at 3 months Reduction in immunosuppressive drug doses Adverse effects Notes Funding source: "This trial was supported by a grant and provision of trial medication from Novartis Pharmaceuticals UK." .. Risk of bias Bias Authors' judgement Support for judgement Random sequence generation (selection bias) Low risk "Randomisation and distribution of trial medication was centrally controlled by Novartis UK" Allocation concealment (selection bias) Low risk Medication distributed by Novartis UK Blinding of participants and personnel (performance bias) All outcomes Low risk "patients and physicians were blinded to the treatment limb" Blinding of outcome assessment (detection bias) All outcomes Unclear risk Insufficient information to permit judgement Incomplete outcome data (attrition bias) All outcomes Low risk All patients accounted for Selective reporting (reporting bias) Low risk Study and review outcomes reported Other bias High risk Funding source: Novartis Jayne 2000 Methods Study design: parallel, open‐label, pragmatic, multicentre, RCT Duration of study: enrolment November 2012 to November 2013 Duration of follow‐up: 28 months Participants Country: France Setting: multicentre (59 sites) Inclusion criteria: > 18 years; had newly diagnosed or relapsing GPA or MPA (defined by the Chapel Hill Consensus nomenclature); in complete remission after induction therapy, combining glucocorticoids and cyclophosphamide, RTX or methotrexate (as decided by each investigator), in accordance with French and international recommendations; BVAS of 0 (score range: 0–63, with higher scores indicating more active disease) defined complete remission. ..
|
